Catabasis Pharmaceuticals Inc (CATB):企業の財務・戦略的SWOT分析

◆英語タイトル:Catabasis Pharmaceuticals Inc (CATB) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH135764FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Catabasis Pharmaceuticals Inc (Catabasis Pharmaceuticals) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes medicines for the treatment of multiple diseases. The company develops its product candidates using its proprietary safely metabolized and rationally targeted (SMART) Linker drug discovery platform for rare diseases, among others. Its product candidate edasalonexent CAT-1004, currently under Phase 3 trial, is an oral small molecule intended for the treatment of Duchenne muscular dystrophy. CAT-5571, an activator of autophagy and the company’s lead product under preclinical stage, is an oral small molecule for the treatment of cystic fibrosis. The company’s CAT-4001 is used for the treatment of neurodegenerative diseases such as Friedreich’s ataxia and amyotrophic lateral sclerosis (ALS). Catabasis Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Catabasis Pharmaceuticals Inc Key Recent Developments

Mar 11,2021: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Mar 02,2021: Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Jan 29,2021: Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
Nov 12,2020: Catabasis Pharmaceuticals reports third quarter 2020 financial results and provides a corporate update
Sep 21,2020: Catabasis Pharmaceuticals names Noah Clauser Chief Financial Officer

This comprehensive SWOT profile of Catabasis Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Catabasis Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Catabasis Pharmaceuticals Inc – Key Information
Catabasis Pharmaceuticals Inc – Overview
Catabasis Pharmaceuticals Inc – Key Employees
Catabasis Pharmaceuticals Inc – Key Employee Biographies
Catabasis Pharmaceuticals Inc – Key Operational Heads
Catabasis Pharmaceuticals Inc – Major Products and Services
Catabasis Pharmaceuticals Inc – History
Catabasis Pharmaceuticals Inc – Company Statement
Catabasis Pharmaceuticals Inc – Locations And Subsidiaries
Catabasis Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Catabasis Pharmaceuticals Inc – Business Description
Catabasis Pharmaceuticals Inc – Corporate Strategy
Catabasis Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Catabasis Pharmaceuticals Inc – Strengths
Catabasis Pharmaceuticals Inc – Weaknesses
Catabasis Pharmaceuticals Inc – Opportunities
Catabasis Pharmaceuticals Inc – Threats
Catabasis Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Catabasis Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Catabasis Pharmaceuticals Inc, Key Information
Catabasis Pharmaceuticals Inc, Key Ratios
Catabasis Pharmaceuticals Inc, Share Data
Catabasis Pharmaceuticals Inc, Major Products and Services
Catabasis Pharmaceuticals Inc, History
Catabasis Pharmaceuticals Inc, Key Employees
Catabasis Pharmaceuticals Inc, Key Employee Biographies
Catabasis Pharmaceuticals Inc, Key Operational Heads
Catabasis Pharmaceuticals Inc, Other Locations
Catabasis Pharmaceuticals Inc, Subsidiaries
Catabasis Pharmaceuticals Inc, Key Competitors
Catabasis Pharmaceuticals Inc, SWOT Analysis
Catabasis Pharmaceuticals Inc, Ratios based on current share price
Catabasis Pharmaceuticals Inc, Annual Ratios
Catabasis Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Catabasis Pharmaceuticals Inc (CATB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Unilever Plc (ULVR):企業の財務・戦略的SWOT分析
    Unilever Plc (ULVR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Onorach Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Onorach Ltd (Onorach) is a contract research organization that provides clinical support services. The organization service portfolio includes tailored clinical trial support, clinical plan development, protocol design, regulatory, quality management, clinical operations management, patient …
  • Parkway Properties Inc:企業のM&A・事業提携・投資動向
    Parkway Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Parkway Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • ArmorWorks Enterprises, LLC:企業の戦略・SWOT・財務情報
    ArmorWorks Enterprises, LLC - Strategy, SWOT and Corporate Finance Report Summary ArmorWorks Enterprises, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • LifePoint Health Inc (LPNT):製薬・医療:M&Aディール及び事業提携情報
    Summary LifePoint Health Inc (LifePoint) is a healthcare service provider which operates community hospitals, physician practices, outpatient centers, post-acute facilities and regional health systems. The company along with its subsidiaries delivers a range of medical and surgical services to non-u …
  • Editas Medicine Inc (EDIT):企業の財務・戦略的SWOT分析
    Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Intercontinental Exchange, Inc.:企業のM&A・事業提携・投資動向
    Intercontinental Exchange, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Intercontinental Exchange, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • XCR Diagnostics Inc:企業の製品パイプライン分析
    Summary XCR Diagnostics Inc (XCR Diagnostics) is a designer and developer of real-time PCR assays. The company’s products include brucella abortus detection assay, brucella ovis detection assay and custom real time PCR master mix. It offers services such as assay design services, assay design and co …
  • Kazakhtelecom (KZTK):企業の財務・戦略的SWOT分析
    Kazakhtelecom (KZTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • General Electric Company:戦略・SWOT・企業財務分析
    General Electric Company - Strategy, SWOT and Corporate Finance Report Summary General Electric Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Service Corporation International (SCI):企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Electricity Generating Authority of Thailand:発電所・企業SWOT分析
    Electricity Generating Authority of Thailand - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • Kinnov Therapeutics SAS-製薬・医療分野:企業M&A・提携分析
    Summary Kinnov Therapeutics SAS (Kinnov) is a research and development company that discovers and develops therapies against addiction. The company’s pipeline product include KT-110, a pharmaceutical composition used as a therapy for addiction diseases. Its antagonist of alpha1-adrenergic receptors …
  • APEIRON Biologics AG:製薬・医療:M&Aディール及び事業提携情報
    Summary APEIRON Biologics AG (APEIRON) is a clinical-stage biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. The company’s pipeline products include APN01, APN301, APN311, APN401, APN411, APN421 and APN431. Its …
  • Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Husky Energy Inc (Husky) is an integrated energy company. It operates across the oil and gas value chain. Its upstream operations include the exploration, development and production of crude oil, bi …
  • Barton Malow Company:企業の戦略・SWOT・財務情報
    Barton Malow Company - Strategy, SWOT and Corporate Finance Report Summary Barton Malow Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Temple University-製薬・医療分野:企業M&A・提携分析
    Summary Temple University (Temple) is an educational and research university that offers undergraduate and graduate courses. The university offers undergraduate courses in various fields which include arts, media and communication, medicine, engineering, pharmacy and others. Temple offers its degree …
  • Emergent BioSolutions Inc (EBS):製薬・医療:M&Aディール及び事業提携情報
    Summary Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It …
  • Formosa Laboratories Inc (4746):製薬・医療:M&Aディール及び事業提携情報
    Summary Formosa Laboratories Inc (Formosa Laboratories) is a producer of active pharmaceutical ingredients and UV-filters. The company’s active pharmaceutical ingredients include cholesterol and phosphate binders, anticancers, CNS agents, immunomodulators, MRI enhancing agents, anti-inflammatory and …
  • Bhansali Engineering Polymers Ltd (BEPL):企業の財務・戦略的SWOT分析
    Summary Bhansali Engineering Polymers Ltd (BEPL), formerly Bhansali Steel Ltd is a petrochemical company that manufactures and markets acrylonitrile butadiene styrene. The company's products include general ABS, extrusion ABS, flame retardant ABS, ABS-GF or SAN-GF, PMMA-ABS, PVC modifier, PC or ABS …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆